Agenus Tumor Reductions in Neoadjuvant MSS Colon Cancer

  Agenus Inc.  (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced results from an investigator-sponsored trial (IST) of botensilimab and balstilimab (BOT/BAL) in the neoadjuvant setting for colon cancer. Data were presented at the 2024 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Munich, Germany.

https://www.biospace.com/article/releases/significant-tumor-reductions-in-neoadjuvant-mss-colon-cancer-patients-treated-with-botensilimab-balstilimab-presented-at-esmo-gi-conference/